Overview

A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients

Status:
Recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

Summary

An autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients.

Phase:

Phase 2

Details

Lead Sponsor:

Sheba Medical Center

Treatments:

Aldesleukin